VERAXA Biotech (NASDAQ: VRXA) has appointed Carl von Halem as Interim Chief Financial Officer, succeeding Torsten Bürgermeister, effective July 10, 2026. VERAXA is in late-stage discussions with a permanent successor to support its next phase of expansion and operational growth.
According to VERAXA, von Halem, currently CFO of Xlife Science and Managing Director of Xlife Science GmbH, played a key role in taking VERAXA public and has deep knowledge of its operations, strategy, and structure. He also serves on boards of Xlife Science portfolio companies and has prior experience in fintech and renewable energy.
VERAXA Biotech (NASDAQ: VRXA) issued a business update highlighting its focus on novel BiTAC®-based cancer therapies and partnering plans. The company is prioritizing BiTAC T cell engagers and bispecific ADCs, intends to monetize non-BiTAC assets, and aims to have lead BiTAC-TCE candidate VXA-102 IND/CTA-ready by early 2028.
VERAXA currently has four BiTAC-based T cell engager programs for solid tumors and two bispecific ADC programs, including a partnered bsADC with OmniAb. Antibody VXA-901 for AML and a HER2-targeting ADC are available for partnering amid strong industry interest in TCE and ADC technologies.
VERAXA Biotech (NASDAQ: VRXA) has initiated cell line development for its lead BiTAC T‑cell engager (BiTAC‑TCE), engaging ATUM to apply its Leap-In Transposase technology. This collaboration supports generation of stable clonal cell lines, a key step toward IND/CTA‑enabling activities and future clinical development of VERAXA’s most advanced BiTAC‑TCE candidate.
VERAXA Biotech (NASDAQ: VRXA) expanded its R&D hub in Heidelberg, increasing laboratory space by more than 60%. The added space supports planned R&D team growth, new lab equipment, and full R&D infrastructure build-out.
The expansion backs VERAXA’s proprietary BiTAC™-TCE and BiTAC™-ADC cancer therapy programs as they move toward early clinical development.
VERAXA Biotech (NASDAQ: VRXA) reported in vitro proof-of-concept data for its novel BiTAC-ADC technology, showing selective, dose-dependent killing of breast cancer cells and 3D tumor spheroids while sparing healthy cells. The company will seek partnering opportunities for its BiTAC-ADC and BiTAC-TCE platforms at BIO International 2026.